Bliss GVS Pharma Limited (BLISSGVS.NS) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-99.6%

₹2.82

vs ₹635.95 price

Levered DCF

₹88.41

After debt service

Piotroski score

6 / 9

Average

Altman Z-score

17.76

Safe zone

Rating

Overall 3 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	18.76×	14.87×	16.05×	10.42×	52.81×	14.84×	10.68×	15.04×
P/B	2.03×	1.2×	1.25×	0.84×	0.97×	1.26×	1.41×	2.88×
P/S	2.61×	1.56×	1.58×	0.99×	1.08×	1.79×	1.52×	2.1×
EV / EBITDA	10.25×	10.49×	8.65×	6.04×	11.6×	8.87×	7.71×	9.97×
Gross margin	54.2%	48.9%	32.6%	46.9%	47.0%	42.2%	35.5%	30.9%
Operating margin	14.1%	35.1%	16.1%	13.5%	12.9%	14.6%	16.3%	17.0%
Net margin	13.9%	10.4%	9.9%	9.5%	2.0%	12.0%	14.3%	14.0%
Current ratio	4.02×	4.81×	5.08×	3.61×	3.33×	3.76×	3.33×	3.35×
Debt / equity	0.02×	0.08×	0.1×	0.12×	0.13×	0.15×	0.17×	0.16×
Interest coverage	10.87×	34.97×	17.81×	9.72×	20.04×	15.06×	14.69×	34.22×
Dividend yield	0.4%	0.4%	0.4%	0.7%	0.7%	0.5%	1.2%	0.4%
Payout ratio	8.2%	6.5%	7.1%	7.7%	35.4%	8.1%	12.9%	6.7%

Key metrics by fiscal year

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	10.8%	8.0%	7.8%	8.0%	1.8%	8.5%	13.2%	19.2%
Return on invested capital	7.3%	17.2%	7.7%	7.1%	4.2%	6.1%	9.3%	13.7%
Return on assets	8.7%	6.5%	6.2%	6.1%	1.4%	6.4%	9.5%	13.7%
Free cash flow yield	3.4%	2.4%	10.2%	-8.1%	7.7%	5.4%	-1.4%	-0.2%
Earnings yield	5.3%	6.7%	6.2%	9.6%	1.9%	6.7%	9.4%	6.7%
Enterprise value	₹24.1B	₹13.3B	₹12.9B	₹8.2B	₹8.8B	₹11.3B	₹11.5B	₹19.5B
Net debt / EBITDA	-0.06×	0.51×	0.52×	0.57×	1.15×	0.86×	0.74×	0.45×
Cash conversion cycle (days)	244	250	233	205	229	325	284	194